Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
What adjuvant therapy would you offer a TNBC patient with residual disease after receiving the neoadjuvant KEYNOTE-522 regimen?
Answer from: Medical Oncologist at Academic Institution
Safety is pembro and cape was provided in phase I trials. Risk and benefit weighing is important when discussing with patients.
Sign in or Register to read more
12421
Related Questions
What are your top takeaways in Breast Cancer from ASCO 2024?
Do you have concerns about the generalizability of Oncotype testing/Mammaprint testing in making chemotherapy decisions for non-Caucasian women?
Would history of breast cancer deter you from using ospemifene for severe vaginal dryness/dyspareunia?
Would you offer adjuvant endocrine therapy for a postmenopausal female with stage III triple positive multicentric breast cancer (DCIS and invasive ductal carcinoma) s/p neoadjuvant TCHP followed by bilateral mastectomy with no residual disease?
What is your preferred method of surveillance after mastectomy?
How would you decide the duration of ovarian suppression in premenopausal females with early stage ER+ breast cancer?
What neoadjuvant chemotherapy do you suggest for a rapidly growing triple-negative breast cancer?
Is there safety data regarding the use of hormonal IUDs in patients with atypical ductal hyperplasia and other high risk, non-malignant breast lesions?
How would you approach adjuvant therapy for large (≥4 cm), node negative, HR+, HER2- breast cancer in an elderly woman with comorbidities including neuropathy?
Do you follow LFTs in patients on tamoxifen as suggested in the prescribing guidelines?